• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氯胺酮和艾司氯胺酮治疗青少年难治性抑郁症和自杀倾向的系统评价:新希望?

A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?

作者信息

Pardossi Simone, Fagiolini Andrea, Scheggi Simona, Cuomo Alessandro

机构信息

Department of Molecular Medicine, University of Siena School of Medicine, 53100 Siena, Italy.

出版信息

Children (Basel). 2024 Jun 29;11(7):801. doi: 10.3390/children11070801.

DOI:10.3390/children11070801
PMID:39062250
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11274655/
Abstract

Treating depression in adolescents is a significant challenge, and major depressive disorder (MDD) with suicidal ideation and treatment-resistant depression (TRD) are common and potentially devastating to optimal psychological and physical development in this age group. Suicide is among the leading causes of youth mortality, and TRD occurs in up to 40% of adolescents with MDD. TRD involves severe, persistent symptoms that are hard to treat, significantly reducing functioning and quality of life. We conducted a literature search focusing on key terms related to ketamine and esketamine for MDD with suicidal ideation and TRD in adolescents, aiming to review the potential utility of these molecules in adolescents for these conditions. Ketamine has shown efficacy in reducing depressive symptoms in adolescents with TRD. Esketamine has shown efficacy in reducing depressive symptoms and treating suicidal ideation in adolescents. Both ketamine and esketamine have demonstrated favorable safety and tolerability profiles. Using these drugs for serious conditions like adolescent MDD with suicidal thoughts and TRD can effectively treat symptoms, reduce self-harm and suicide risks, and provide a window for longer-term therapeutic interventions. The prompt and effective treatment of TRD could improve adolescents' quality of life. However, more research is needed to optimize treatment protocols and evaluate long-term effects.

摘要

治疗青少年抑郁症是一项重大挑战,伴有自杀意念的重度抑郁症(MDD)和难治性抑郁症(TRD)在该年龄组中很常见,并且可能对最佳心理和身体发育造成毁灭性影响。自杀是青少年死亡的主要原因之一,TRD在高达40%的患有MDD的青少年中出现。TRD涉及严重、持续且难以治疗的症状,会显著降低功能和生活质量。我们进行了一项文献检索,重点关注与氯胺酮和艾司氯胺酮相关的关键术语,用于治疗青少年伴有自杀意念和TRD的MDD,旨在综述这些分子在青少年中针对这些病症的潜在效用。氯胺酮已显示出对患有TRD的青少年有减轻抑郁症状的疗效。艾司氯胺酮已显示出对青少年有减轻抑郁症状和治疗自杀意念的疗效。氯胺酮和艾司氯胺酮均已证明具有良好的安全性和耐受性。将这些药物用于治疗像伴有自杀念头和TRD的青少年MDD这样的严重病症,可以有效治疗症状、降低自我伤害和自杀风险,并为长期治疗干预提供契机。及时有效地治疗TRD可以改善青少年的生活质量。然而,需要更多研究来优化治疗方案并评估长期效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/11274655/8982928eca59/children-11-00801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/11274655/8982928eca59/children-11-00801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e78a/11274655/8982928eca59/children-11-00801-g001.jpg

相似文献

1
A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?氯胺酮和艾司氯胺酮治疗青少年难治性抑郁症和自杀倾向的系统评价:新希望?
Children (Basel). 2024 Jun 29;11(7):801. doi: 10.3390/children11070801.
2
Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.探索艾氯胺酮作为美国食品药品监督管理局指定的难治性抑郁症和有自杀意图的重度抑郁症治疗突破药物的治疗效果:一项叙述性综述。
Cureus. 2024 Feb 10;16(2):e53987. doi: 10.7759/cureus.53987. eCollection 2024 Feb.
3
Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".关于 Cochrane 综述的评论:“氯胺酮和其他谷氨酸受体调节剂治疗单相重性抑郁障碍成人抑郁症”。
J Psychopharmacol. 2023 Aug;37(8):836-844. doi: 10.1177/02698811221123046. Epub 2022 Oct 11.
4
A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.氯胺酮和艾司氯胺酮治疗难治性抑郁症中自杀观念疗效的系统评价和荟萃分析。
Eur J Clin Pharmacol. 2024 Feb;80(2):287-296. doi: 10.1007/s00228-023-03605-1. Epub 2023 Dec 20.
5
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review.氯胺酮和艾司氯胺酮鼻内制剂治疗重度抑郁症的疗效与安全性:一项系统评价
Pharmaceutics. 2023 Dec 13;15(12):2773. doi: 10.3390/pharmaceutics15122773.
6
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.依他佐辛治疗伴有自杀意念的重性抑郁障碍的疗效和安全性:一项随机对照试验的研究方案。
BMC Psychiatry. 2022 Nov 30;22(1):744. doi: 10.1186/s12888-022-04388-y.
7
Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.重复静脉用艾司氯胺酮对有自杀意念的青少年重度抑郁症的疗效:一项随机、活性药物对照试验。
J Am Acad Child Adolesc Psychiatry. 2024 May;63(5):507-518. doi: 10.1016/j.jaac.2023.05.031. Epub 2023 Jul 4.
8
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.谷氨酸能系统在自杀性抑郁症中的最新研究进展及艾司氯胺酮的作用
Curr Top Med Chem. 2020;20(7):554-584. doi: 10.2174/1568026620666200131100316.
9
Editorial: Novel Approaches to the Treatment of Suicidality and Depression in Youth.社论:青少年自杀意念和抑郁治疗的新方法。
J Am Acad Child Adolesc Psychiatry. 2024 May;63(5):500-501. doi: 10.1016/j.jaac.2023.06.019. Epub 2023 Jul 6.
10
The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).氯胺酮和艾司氯胺酮与自杀倾向之间的关联:向美国食品药品监督管理局不良事件报告系统(FAERS)提交的报告。
Expert Opin Drug Saf. 2024 Jun 21:1-6. doi: 10.1080/14740338.2024.2368827.

引用本文的文献

1
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.艾氯胺酮联合选择性5-羟色胺再摄取抑制剂(SSRI)或5-羟色胺及去甲肾上腺素再摄取抑制剂(SNRI)治疗难治性抑郁症
JAMA Psychiatry. 2025 Apr 2. doi: 10.1001/jamapsychiatry.2025.0200.

本文引用的文献

1
Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review.氯胺酮用于儿童和青少年的情绪障碍、焦虑及自杀倾向:一项系统综述
Eur Child Adolesc Psychiatry. 2025 Jan;34(1):141-157. doi: 10.1007/s00787-024-02458-y. Epub 2024 May 16.
2
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.探索青少年治疗抵抗性抑郁症中氯胺酮反应的预测因子。
J Child Adolesc Psychopharmacol. 2024 Mar;34(2):73-79. doi: 10.1089/cap.2023.0047. Epub 2024 Jan 3.
3
Suicide and Suicide Risk in Adolescents.
青少年自杀与自杀风险
Pediatrics. 2024 Jan 1;153(1). doi: 10.1542/peds.2023-064800.
4
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study).依他佐辛鼻喷剂联合标准治疗对伴有自杀意念的重性抑郁障碍患者的疗效和安全性:ASPIRE I 研究(一项随机、双盲、安慰剂对照研究)亚洲队列的亚组分析。
Asia Pac Psychiatry. 2023 Dec;15(4):e12548. doi: 10.1111/appy.12548. Epub 2023 Sep 28.
5
Ketamine use in pediatric depression: A systematic review.儿童抑郁症中氯胺酮的使用:系统评价。
Psychiatry Res. 2022 Nov;317:114911. doi: 10.1016/j.psychres.2022.114911. Epub 2022 Oct 15.
6
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression.氯胺酮与经颅磁刺激治疗一名难治性抑郁症青少年患者
J Child Adolesc Psychopharmacol. 2023 Sep;33(7):297-303. doi: 10.1089/cap.2023.29245.bjc.
7
Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial.重复剂量艾司氯胺酮对患有重度抑郁症和自杀意念的青少年的短期认知影响:一项随机对照试验。
Child Adolesc Psychiatry Ment Health. 2023 Sep 14;17(1):108. doi: 10.1186/s13034-023-00647-2.
8
Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.重复静脉用艾司氯胺酮对有自杀意念的青少年重度抑郁症的疗效:一项随机、活性药物对照试验。
J Am Acad Child Adolesc Psychiatry. 2024 May;63(5):507-518. doi: 10.1016/j.jaac.2023.05.031. Epub 2023 Jul 4.
9
Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression.重复静脉注射艾司氯胺酮治疗青少年焦虑性抑郁与非焦虑性抑郁的疗效。
Gen Psychiatr. 2023 Jun 21;36(3):e101007. doi: 10.1136/gpsych-2023-101007. eCollection 2023.
10
Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions.氯胺酮在儿童和青少年精神病学中的应用:治疗抵抗性抑郁症的新数据、来自成人的见解以及未来方向。
Curr Psychiatry Rep. 2023 Aug;25(8):337-344. doi: 10.1007/s11920-023-01432-w. Epub 2023 Jun 30.